Illumina CEO 'Optimistic' about Array Business as Q1 Sales Spike 47 Percent | GenomeWeb

This story was originally posted on April 27.

By Justin Petrone

"Continued success" of its next-generation sequencing instruments and "strong" array sales contributed to a 47-percent increase in Illumina's first-quarter revenue.

The San Diego-based firm said total receipts for the three months ended April 3 rose to $282.5 million from $192.1 million for year over year. Product revenues rose 53 percent to $266.7 million from $173.7 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.